Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celgene Pays Acceleron $25M up front under anaemia drug partnership

This article was originally published in Scrip

Executive Summary

Celgene is paying privately held Acceleron Pharma $25 million up front under a deal to jointly develop and commercialise ACE-536, a ligand trap that inhibits members of the transforming growth factor- (TGF) beta "superfamily" involved in the late stages of erythropoiesis – the process of generating red blood cells – as a treatment for anaemia.


Related Content

Celgene Notches A Needed Win As Acceleron-Partnered Luspatercept Succeeds In MDS
Finance Watch: Genocea, Mateon Shift Strategies, Cut Jobs To Preserve Cash


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts